April 15, 2025 07:20 AM EDTUpdated 10:08 AM

J&J, pharma's earnings bellwether, maintains guidance as tariffs loom

Max Gelman

Senior Editor

Johnson & Johnson is maintaining its 2025 financial guidance and raising its sales forecast despite President Donald Trump’s efforts to tariff pharmaceuticals.

The growth projection …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J, pharma's earnings bellwether, maintains guidance as tariffs loom

Max Gelman

Senior Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Trump pledges his support for a change to the IRA long sought by drugmakers

J&J's Duato says 'not tariffs, but tax policy' is best way to boost US manufacturing

Pharma tariffs could leave little room to hide with sweeping probe underway

Sanofi’s Kymab-originated inflammatory drug flunks mid-stage asthma trial

Exclusive: A small biotech will bring Roche's Angelman drug back to life

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

J&J, phar­ma's earn­ings bell­wether, main­tains guid­ance as tar­iffs loom

Senior Editor

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

J&J, pharma's earnings bellwether, maintains guidance as tariffs loom